VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment
Vaccine·
- DOI
- 10.1016/j.vaccine.2022.05.022
- PMID
- 35659449
- PMCID
- PMC9159788
- OpenAlex
- W4281947035
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The registry addresses a recognized barrier in pandemic response by providing a centralized infrastructure to accelerate clinical trial recruitment across European countries, potentially shortening the timeline for vaccine and treatment development during infectious disease outbreaks.
Structured evidence summary
Research question
The article describes the establishment and implementation of a European volunteer registry designed to facilitate recruitment of participants for COVID-19 clinical trials across multiple countries.
Study design
This is a descriptive report of a registry infrastructure. Volunteers complete a questionnaire providing demographic information, contact details, comorbidities, SARS-CoV-2 infection and vaccination history, and willingness to travel for trial participation.
Population and setting
The registry operates in 12 European countries with questionnaires available in 14 languages, targeting both adults and children who reside in participating countries and are interested in COVID-19 clinical trial participation. As of May 2022, over 36,000 volunteers had registered, predominantly from Germany.
Main findings
Within the first year of operation, the registry matched more than 15,000 volunteers to clinical trials, with all matched individuals located in Germany. The registry was operational in 12 countries and in the implementation phase in 5 additional countries at the time of reporting.
Public-health relevance
The registry addresses a recognized barrier in pandemic response by providing a centralized infrastructure to accelerate clinical trial recruitment across European countries, potentially shortening the timeline for vaccine and treatment development during infectious disease outbreaks.
Important limitations
This summary is limited to the supplied single-article abstract and metadata. The original paper is required for decision-grade interpretation of registry validation, data quality measures, representativeness of the volunteer pool, and operational challenges encountered during implementation.
GIDS interpretation
The classifier links identify this article as relevant to COVID-19, vaccination, and treatment topics across 16 European and Middle Eastern countries. These links indicate where the registry infrastructure was geographically discoverable during the pandemic period but do not establish a connection to current surveillance signals.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.